Navigation Links
Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole) to improve the gastrointestinal safety of antiplatelet therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. "In a previous clinical trial we demonstrated that the absorption of CGT-2168 is equivalent to that of Plavix, and that the omeprazole component within CGT-2168 does not interfere with the metabolism of the clopidogrel component," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

An independent study published this week in the Journal of the American College of Cardiology showed that commercially available omeprazole significantly decreases the antiplatelet activity of Plavix when the two medicines are co-administered. "This finding is consistent with our own earlier clinical data that revealed an adverse drug interaction between Plavix and Prilosec(R) (marketed omeprazole), and may raise serious concerns for patients and practitioners," Dr. Goldsmith said. "However, these findings contrast with the properties we have observed with our unique formulation, CGT-2168. We expect the CG106 trial to confirm that CGT-2168 exhibits full antiplatelet activity and avoids the drug-drug interaction reported with the individual drugs on the market today."

Separately, Cogentus has begun COGENT-1, a global Phase 3 trial that will evaluate the clinical benefits
'/>"/>

SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
2. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... developing better, faster and affordable treatments for tuberculosis (TB), ... Senior Vice President, Market Access. Ms. Robertson joins the ... the company,s business in Sub-Saharan Africa and ... will oversee the TB Alliance,s efforts to ensure beneficial ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2genae Opens Offices in London 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
... SAN ANTONIO, July 12, 2011 Sevocity, the ... that Sevocity v11.1 has achieved full certification through ... and is a CCHIT Certified® 2011 Ambulatory EHR. ... usability rating, the highest level awarded by CCHIT. ...
... Surgical Care Affiliates (SCA), a national leader in ... and surgery departments, announced today it has entered into ... subsidiary of Suburban Hospital Healthcare System, Inc., a member ... in the Bethesda and Montgomery County areas. ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2Surgical Care Affiliates Announces Agreement With Suburban Outpatient Surgery Center 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... used birth control pills containing high-dose estrogen and a ... cancer, whereas women using some other formulations did not, ... a journal of the American Association for Cancer Research. ... contraceptives [birth control pills] in the past year is ... never or former oral contraceptive use, and that this ...
(Date:7/31/2014)... 2014 Developer Jamestown, L.P., has been ... Ponce City Market project in Atlanta’s Old Fourth Ward, ... Company building into best-in-class office, housing, and retail spaces. ... experience with their construction webcam service to assess how ... a construction camera for monitoring and documentation ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , opened ... Horn Road in Lake Leelanau. Joining the Northern Loop of ... the 25th winery along the trail. The winery will participate ... making its trail event debut during the Harvest Stompede on ... and Faye Mathia opened the boutique winery in the former ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... 28 Dr. Jeffrey Cummings, Medical,Director of The ... the prestigious Ronald and Nancy Reagan Research Award ... themselves to, discovering new,treatments and methods of care ... In his speech of acceptance at the annual ...
... finds molecule boosted cells eliminating colitis, Crohn,s symptoms , , ... by intestinal bacteria can eliminate symptoms of inflammatory bowel ... includes Crohn,s disease and ulcerative colitis. , It ... and other mammals contain about 1,000 different species of ...
... of Pennsylvania School of Medicine have shown how Argos, ... binding growth factors that promote the progression of cancer. ... new drug designs for inhibiting cancer. The study appeared ... Many types of tumors grow because of over-expression of ...
... 300-Page Book, with Foreword by FDA,s Janet Woodcock, ... WASHINGTON, May 28 Now that the Food ... the safe use of,pharmaceuticals, drug manufacturers can be ... their marketing on,existing pharmaceuticals., To help pharmaceutical ...
... DRAXIS Health Inc. ("DRAXIS"),(TSX: DAX) (NASDAQ: DRAX ) ... all of DRAXIS, common shares have been acquired by,an ... common share. As a result, DRAXIS common stock is ... on the Toronto Stock Exchange at,market close on Thursday, ...
... engineer. As a youngster, she had a fascination with ... Today, Sullivan, an assistant professor of chemical engineering at ... applying her knowledge and talents to an area critical ... drugs and gene therapies to diseased and damaged cells ...
Cached Medicine News:Health News:Gut Bacteria Fights Inflammatory Bowel Disease 2Health News:Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:DRAXIS Announces Completion of Sale to Jubilant 2Health News:DRAXIS Announces Completion of Sale to Jubilant 3Health News:DRAXIS Announces Completion of Sale to Jubilant 4Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 2Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 3
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Medicine Products: